With clear PhII win in IBD, Prometheus thwarts Pfiz­er com­par­isons as it fol­lows Hu­mi­ra 'play­book'

Prometheus Bio­sciences re­port­ed a clear Phase II win in two in­flam­ma­to­ry bow­el dis­ease con­di­tions in a clin­i­cal de­vel­op­ment race with Pfiz­er, plant­i­ng the biotech’s flag in a field of an­ti­bod­ies at­tempt­ing to go against black box-cor­nered JAK in­hibitors and Ab­b­Vie’s Hu­mi­ra.

Shares $RXDX have soared since the sum­mer — a small dip last week notwith­stand­ing when ri­val Pfiz­er teamed up with Roivant on a new com­pa­ny for their com­pet­ing an­ti-TL1A mon­o­clon­al an­ti­body. And they sky­rock­et­ed once again Wednes­day morn­ing, climb­ing from $36 apiece to more than $100 on the back of two Phase II stud­ies: one place­bo-con­trolled in ul­cer­a­tive col­i­tis and the oth­er an open-la­bel tri­al in pa­tients with Crohn’s dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER